MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

Publication date: Available online 6 May 2016 Source:Revista Portuguesa de Pneumologia (English Edition) Author(s): F. Barata, H. Queiroga, E. Teixeira, M.T. Almodovar, B. Parente, M. Soares
Source: Revista Portuguesa de Pneumologia - Category: Respiratory Medicine Source Type: research